Chemotherapy and similar treatments aimed at eliminating cancer cells often adversely affect patients’ immune cells. Each year, this results in tens of thousands of cancer patients suffering from weakened immune systems, making them susceptible to potentially fatal infections. Physicians are tasked with balancing the dosage of chemotherapy—enough to kill cancer cells but not so much as to dangerously reduce the patient’s white blood cell count, leading to neutropenia. This condition not only impacts health but can also lead to social isolation between chemotherapy sessions. Traditionally, monitoring of white blood cells has been limited to blood tests. Now, a new at-home white blood cell monitor offers doctors the ability to remotely monitor their patients’ health more comprehensively. This device, which avoids blood draws, uses light to scan the skin at the top of the fingernail and employs artificial intelligence (AI) to identify critically low levels of white blood cells. Based on ...
Drugdu.com expert’s response: 1.Pre-preparation Stage ①Understanding Indonesian Market and Regulations: Firstly, Chinese companies need to understand Indonesia’s import regulations, regulatory requirements, and market demand for pharmaceuticals, healthcare products, and food ingredients, ensuring that exported products comply with Indonesian standards and regulations. ②Signing Trade Contracts: After clarifying market demand and regulatory requirements, Chinese companies should sign trade contracts with Indonesian importers or buyers, clarifying product specifications, quantity, price, delivery method, and other terms. 2.Export Declaration Stage ①Preparing Export Documents: Chinese companies need to prepare necessary export documents, including commercial invoices, packing lists, certificates of origin, export licenses (if required), etc. These documents must accurately reflect information such as product names, quantities, specifications, prices, etc. ②Export Declaration: Chinese companies submit export declaration forms and related documents to customs authorities for export declaration procedures. Customs authorities will review the information and documents to ensure they are complete and valid, and verify the ...
Organizer: Reed Sinopharm Exhibitions Date: October 16-18, 2024 Venue: No. 1399 Huizhan 1st Road, Baqiao District, Xi’an, Shaanxi Province Exhibition hall:Xi’an International Convention and Exhibition Center Product range: Pharmaceutical APIs, Pharmaceutical Excipients, Natural Extracts, Chemical Reagents, Intermediates, Fine Chemical Raw Materials, Key Raw Materials, Food Ingredients and Additives, Veterinary Drug Raw Materials, Feed Ingredients and Additives, Health Product Ingredients and Additives, Biotechnology, Pharmaceutical R&D Services, Contract Manufacturing Services, Registration and Pharmaceutical Services, Training Services Exhibition Introduction: As the longest-running exhibition in China’s pharmaceutical industry, API China – China International Pharmaceutical API Exhibition was first held in 1968. The exhibits cover more than 50,000 types of APIs in 24 categories, as well as all auxiliary materials, functional ingredients, internal and external packaging materials, production and testing equipment required for the production of pharmaceuticals and health products.
Drugdu.com expert’s response: Flexible circuit boards (FPC) are widely used in medical devices, especially in scenarios that require high precision, high reliability, and high stability. Due to their strong flexibility and adaptability, FPC can be designed and manufactured according to the shape and size of the product, making them ideal for applications such as electrocardiographs, medical probes, and medical imaging devices. In addition, FPC also has characteristics such as vibration resistance, impact resistance, and anti-aging, further improving its reliability in medical devices.
Much like the mythological navigator from which it takes its name, Barinthus Biotherapeutics is steering a new course of pipeline prioritisation and restructuring by shelving its prostate cancer candidate and a major workforce reduction. The UK-based T cell specialist – formerly known as Vaccitech – said it will prioritise its pipeline to focus on two of its immunotherapy candidates, VTP-300 and VTP-1000, in chronic hepatitis B and coeliac disease indications respectively. Shares in the Nasdaq-listed Barinthus opened 4.7% lower when the market opened on 13 June following the company announcement on 12 June. Barinthus’ market cap is $73m. As part of the pipeline shuffle, the biopharma said that it expects to undergo a restructuring which will include reducing its employee number by around a quarter. The company currently has a headcount of around 130 employees, according to GlobalData. Barinthus also plans to extend its cash runway into Q2 of 2026, ...
Flagship Pioneering and ProFound Therapeutics have entered a partnership to develop new therapeutics for the treatment of obesity. The collaboration marks the first initiative executed under Flagship’s Pioneering Medicines deal with Pfizer announced in July 2023. Pioneering Medicines is the in-house drug discovery and development unit of Flagship and will spearhead the partnership’s efforts with Pfizer. ProFound’s ProFoundry Platform will be deployed with Pioneering Medicines’ capabilities in drug development to discover new proteins and assess their therapeutic potential to treat obesity. ProFound Therapeutics CEO and Flagship Pioneering CEO-partner John Lepore stated: “We are thrilled to be part of the Flagship and Pfizer partnership and to collaborate with Pioneering Medicines to discover and validate novel proteins that have the potential to lead to innovative, first-in-class medicines for patients with obesity. “Through our ProFoundry Platform, we have discovered and validated an extensive library of novel proteins that unlock a new universe of ...
The Trinity Challenge has announced the winners of its second competition (the Trinity Challenge on Antimicrobial Resistance), aimed at tackling the escalating threat of antimicrobial resistance (AMR). The awarded projects focus on addressing critical data gaps in communities and lower-income countries, which are disproportionately impacted by antibiotic-resistant infections. IIIT-Delhi announces that the project “AMRSense: Empowering Communities with a Proactive One Health Ecosystem,” led by Prof Tavpritesh Sethi in collaboration with CHRI-PATH, 1mg.com, and ICMR, has secured the joint second prize. The project shares this honor with “OASIS: OneHealth Antimicrobial Stewardship for Informal Health Systems,” also from India. Each joint second prize winner will receive £600,000 in funding over the next three years. All winners will also benefit from ongoing post-award innovation and scaling support. AMRSense addresses the challenges of engaging, motivating, and training community health workers (CHWs) in AMR surveillance and management, compounded by the lack of a comprehensive data ...
Drugdu.com expert’s response: The benefits and impacts of requiring an EU Representative for CE certification can be summarized as follows: Benefits : 1.Communication Bridge: An EU Representative serves as an intermediary between manufacturers and EU authorities, effectively communicating and handling technical, regulatory, and after-sales issues related to products. This bridging role significantly simplifies the communication process between manufacturers and EU authorities, improving the efficiency of problem-solving. 2.Compliance Assurance: Through an EU Representative, manufacturers can ensure their products meet EU regulatory requirements, mitigating the risk of compliance violations due to unfamiliarity with local regulations. The EU Representative’s familiarity and understanding of EU regulations can provide manufacturers with guidance and support in terms of compliance. 3.Clear Responsibility: In the event of product issues, EU authorities can directly contact the EU Representative to take prompt action, such as product recalls. This clear responsibility approach enhances the efficiency of problem resolution, reducing delays ...
Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance imaging (mpMRI). Now, a cost-effectiveness analysis has revealed that using biparametric magnetic resonance imaging (bpMRI) as an initial screening tool is less cost-effective than the traditional approach of first-line PSA testing followed by mpMRI. This conclusion held true even when assuming no cost for bpMRI, indicating that the financial savings do not compensate for the drawbacks of using the first-line MRI approach. A team of researchers from Fred Hutchinson Cancer Center (Seattle, WA, USA), in collaboration with other institutions, developed a microsimulation model to compare the effectiveness and cost-efficiency of first-line bpMRI versus first-line PSA with reflex mpMRI for prostate cancer screening. The study showed that initiating screening with MRI significantly increased the incidence of false positives, unnecessary prostate biopsies, and overdiagnoses, without a corresponding ...
Organiser:Iran Pharmaceutical Industry Federation Time:October 2nd to 4th, 2024 address:Mashhad Exhibition and Convention Center, Iran Exhibition hall:Mashad Fair Ground Product range: Pharmaceutical machinery: preparation production equipment, pharmaceutical water equipment, traditional Chinese medicine processing equipment, refrigeration equipment, etc Packaging equipment and materials: aluminum-plastic packaging machine, filling machine, tablet press, labeling machine, inkjet printer, anti-counterfeiting printing and packaging and packaging production line, bar code composite technology equipment, adhesive printing and packaging equipment, plastic packaging products, packaging container forming, filling and sealing machine, cartoning packaging machine, bag packaging machine, multi-function bottled packaging machine, glass packaging products and medicinal packaging materials production equipment, etc Laboratory equipment/analysis and testing: laboratory equipment and devices, laboratory consumables, chemical reagents, biochemical/analytical instruments, biotechnology analysis and testing instruments, pharmaceutical testing equipment, food analysis and testing instruments, pharmaceutical industry analysis instruments, etc Fluid equipment: sanitary pumps, valves, fluid engineering, pipes and pipe fittings, microfiltration, ultrafiltration, etc Clean system: clean air ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.